; and (B) for which there are no blocking patents or exclusivities that may receive expedited review, except where the drug was approved pursuant to a suitability petition under section 505(j)(2)(C). . (b) Report on contracts Section 510(j) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360(j) ) is amended by adding at the end the following: (5) Each person who registers with the Secretary under this section shall report to the Secretary any contract with a contract manufacturing organization with respect to any drug such person manufacturers, distributes, or compounds, including the start date and end date of such contract. . (c) Discontinuance or interruption in the production of life-Saving drugs Section 506C(a) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356c(a) ) is amended by striking of a drug— and all that follows through the end of paragraph (2) and inserting of a drug . (d) Decrease in manufacturers of drugs Chapter V of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 351 et seq.) is amended by inserting after section 506C–1 the following: 506C–2. Decrease in manufacturers of generic drugs (a) In general If the Secretary determines that the number of manufacturers of a drug approved under section 505 or a biological product licensed under section 351 is less than 2, the Secretary may— (1) with respect to a manufacturer with fewer than 500 employees, including employees of affiliates of the manufacturer, waive the prescription drug application fees under sections 736(a), 744B(a), or 744H(a); (2) expedite the review of applications for the drug under section 505(j) or section 351(k) of the Public Health Service Act until the number of manufacturers of the drug is at least 4